{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:58:22Z","timestamp":1767707902958,"version":"3.48.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Central Plains Science and Technology Innovation Leading Talent Project","award":["224200510023"],"award-info":[{"award-number":["224200510023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15329-9","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:52:50Z","timestamp":1767707570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elevated levels of SLC38A1 are correlated with an unfavorable prognosis, as well as accelerated cell proliferation and metastasis in lung adenocarcinoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Tian","family":"Xia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun-Xian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"issue":"3","key":"15329_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04692-1","volume":"13","author":"YJ Chen","year":"2022","unstructured":"Chen YJ, Hong WF, Liu ML, Guo X, Yu YY, Cui YH, et al. An integrated bioinformatic investigation of mitochondrial solute carrier family 25 (SLC25) in colon cancer followed by preliminary validation of member 5 (SLC25A5) in tumorigenesis. Cell Death Dis. 2022;13(3):237.","journal-title":"Cell Death Dis"},{"issue":"12","key":"15329_CR2","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/s43018-022-00470-2","volume":"3","author":"F Cappellesso","year":"2022","unstructured":"Cappellesso F, Orban MP, Shirgaonkar N, Berardi E, Serneels J, Neveu MA, et al. Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer. Nat Cancer. 2022;3(12):1464\u201383.","journal-title":"Nat Cancer"},{"issue":"4","key":"15329_CR3","doi-asserted-by":"publisher","first-page":"776","DOI":"10.4149\/neo_2022_211230N1854","volume":"69","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Zhou X, Li Y, Gao X. Solute carrier organic anion transporter family member 4A1 promotes colorectal cancer progression and is regulated by miR-1224-5p. Neoplasma. 2022;69(4):776\u201384.","journal-title":"Neoplasma"},{"issue":"1","key":"15329_CR4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.21873\/invivo.13076","volume":"37","author":"CL Liu","year":"2023","unstructured":"Liu CL, Cheng SP, Huang WC, Chen MJ, Lin CH, Chen SN, et al. Aberrant expression of solute carrier family 35 member A2 correlates with tumor progression in breast cancer. In Vivo. 2023;37(1):262\u20139.","journal-title":"In Vivo"},{"issue":"1","key":"15329_CR5","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1080\/21655979.2021.1962485","volume":"12","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Liu Y, Chen P, Shi X, Liu Y, Shi L, et al. Solute carrier family 12 member 8 (SLC12A8) is a potential biomarker and related to tumor immune cell infiltration in bladder cancer. Bioengineered. 2021;12(1):4946\u201361.","journal-title":"Bioengineered"},{"issue":"1","key":"15329_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12935-023-03082-7","volume":"23","author":"P Zheng","year":"2023","unstructured":"Zheng P, Mao Z, Luo M, Zhou L, Wang L, Liu H, et al. Comprehensive bioinformatics analysis of the solute carrier family and preliminary exploration of SLC25A29 in lung adenocarcinoma. Cancer Cell Int. 2023;23(1):222.","journal-title":"Cancer Cell Int."},{"issue":"2","key":"15329_CR7","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.18632\/aging.205446","volume":"16","author":"FM Wang","year":"2024","unstructured":"Wang FM, Xu LQ, Zhang ZC, Guo Q, Du ZP, Lei Y, et al. SLC7A8 overexpression inhibits the growth and metastasis of lung adenocarcinoma and is correlated with a dismal prognosis. Aging (Albany NY). 2024;16(2):1605\u201319.","journal-title":"Aging (Albany NY)."},{"issue":"1","key":"15329_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11596-017-1690-3","volume":"37","author":"FF Zhou","year":"2017","unstructured":"Zhou FF, Xie W, Chen SQ, Wang XK, Liu Q, Pan XK, et al. SLC38A1 promotes proliferation and migration of human colorectal cancer cells. J Huazhong Univ Sci Technolog Med Sci. 2017;37(1):30\u20136.","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"issue":"7","key":"15329_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13540","volume":"51","author":"J Yu","year":"2021","unstructured":"Yu J, Chen X, Li J, Wang F. CircRUNX1 functions as an oncogene in colorectal cancer by regulating circRUNX1\/miR-485-5p\/SLC38A1 axis. Eur J Clin Invest. 2021;51(7):e13540.","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"15329_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.5009\/gnl210542","volume":"17","author":"R Wu","year":"2023","unstructured":"Wu R, Tang S, Wang Q, Kong P, Liu F. Hsa_circ_0003602 contributes to the progression of colorectal cancer by mediating the miR-149-5p\/SLC38A1 axis. Gut Liver. 2023;17(2):267\u201379.","journal-title":"Gut Liver"},{"issue":"5","key":"15329_CR11","first-page":"514","volume":"25","author":"J Xie","year":"2013","unstructured":"Xie J, Chen Z, Liu L, Li P, Zhu X, Gao H, et al. shRNA-mediated Slc38a1 silencing inhibits migration, but not invasiveness of human pancreatic cancer cells. Chin J Cancer Res. 2013;25(5):514\u20139.","journal-title":"Chin J Cancer Res"},{"key":"15329_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-14-70","volume":"14","author":"J Xie","year":"2014","unstructured":"Xie J, Li P, Gao HF, Qian JX, Yuan LY, Wang JJ. Overexpression of SLC38A1 is associated with poorer prognosis in Chinese patients with gastric cancer. BMC Gastroenterol. 2014;14:70.","journal-title":"BMC Gastroenterol"},{"key":"15329_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-343","volume":"13","author":"K Wang","year":"2013","unstructured":"Wang K, Cao F, Fang W, Hu Y, Chen Y, Ding H, et al. Activation of SNAT1\/SLC38A1 in human breast cancer: correlation with p-Akt overexpression. BMC Cancer. 2013;13:343.","journal-title":"BMC Cancer"},{"issue":"25","key":"15329_CR14","doi-asserted-by":"publisher","first-page":"13194","DOI":"10.1074\/jbc.M115.700534","volume":"291","author":"A Br\u00f6er","year":"2016","unstructured":"Br\u00f6er A, Rahimi F, Br\u00f6er S. Deletion of amino acid transporter ASCT2 (SLC1A5) reveals an essential role for transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to sustain glutaminolysis in cancer cells. J Biol Chem. 2016;291(25):13194\u2013205.","journal-title":"J Biol Chem"},{"key":"15329_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5680968","volume":"2021","author":"Y Liu","year":"2021","unstructured":"Liu Y, Yang Y, Jiang L, Xu H, Wei J. High expression levels of SLC38A1 are correlated with poor prognosis and defective immune infiltration in hepatocellular carcinoma. J Oncol. 2021;2021:5680968.","journal-title":"J Oncol"},{"issue":"11","key":"15329_CR16","doi-asserted-by":"publisher","first-page":"20322","DOI":"10.1002\/jcp.28632","volume":"234","author":"Y Li","year":"2019","unstructured":"Li Y, Shao H, Da Z, Pan J, Fu B. High expression of SLC38A1 predicts poor prognosis in patients with de novo acute myeloid leukemia. J Cell Physiol. 2019;234(11):20322\u20138.","journal-title":"J Cell Physiol"},{"issue":"1","key":"15329_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11060-022-03964-2","volume":"157","author":"R Lin","year":"2022","unstructured":"Lin R, Xu Y, Xie S, Zhang Y, Wang H, Yi GZ, et al. Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma. J Neurooncol. 2022;157(1):15\u201326.","journal-title":"J Neurooncol"},{"issue":"9","key":"15329_CR18","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1097\/CAD.0000000000001328","volume":"33","author":"L Liu","year":"2022","unstructured":"Liu L, Su S, Ye D, Yu Z, Lu W, Li X. Long non-coding RNA OGFRP1 regulates cell proliferation and ferroptosis by miR-299-3p\/SLC38A1 axis in lung cancer. Anticancer Drugs. 2022;33(9):826\u201339.","journal-title":"Anticancer Drugs"},{"issue":"18","key":"15329_CR19","doi-asserted-by":"publisher","first-page":"9633","DOI":"10.18632\/aging.205040","volume":"15","author":"Q Guo","year":"2023","unstructured":"Guo Q, Li K, Jiang N, Zhou R, Rao XR, Wu CY. A novel risk model of three gefitinib-related genes FBP1, SBK1 and AURKA is related to the immune microenvironment and is predicting prognosis of lung adenocarcinoma patients. Aging (Albany NY). 2023;15(18):9633\u201360.","journal-title":"Aging (Albany NY)"},{"key":"15329_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1179742","volume":"14","author":"W Zhang","year":"2023","unstructured":"Zhang W, Qu H, Ma X, Li L, Wei Y, Wang Y, et al. Identification of cuproptosis and immune-related gene prognostic signature in lung adenocarcinoma. Front Immunol. 2023;14:1179742.","journal-title":"Front Immunol"},{"key":"15329_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00242","volume":"11","author":"Q Guo","year":"2020","unstructured":"Guo Q, Ke XX, Liu Z, Gao WL, Fang SX, Chen C, et al. Evaluation of the prognostic value of STEAP1 in lung adenocarcinoma and insights into its potential molecular pathways via bioinformatic analysis. Front Genet. 2020;11:242.","journal-title":"Front Genet"},{"issue":"3","key":"15329_CR22","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.21037\/jgo-23-412","volume":"14","author":"Y Huai","year":"2023","unstructured":"Huai Y, Lai L, Ren Y, Yang B, Yu S, Wang S, et al. A risk model constructed using 14 N6-methyladenosine-related lncRNAs as a new prognostic marker that correlates with the immunomodulatory effect and drug sensitivity in colorectal cancer. J Gastrointest Oncol. 2023;14(3):1360\u201377.","journal-title":"J Gastrointest Oncol"},{"key":"15329_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1170758","volume":"11","author":"XW Liu","year":"2023","unstructured":"Liu XW, Xu HW, Yi YY, Zhang SB, Wang SJ. Role of ferroptosis and immune infiltration in intervertebral disc degeneration: novel insights from bioinformatics analyses. Front Cell Dev Biol. 2023;11:1170758.","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"15329_CR24","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.21037\/tcr-23-227","volume":"12","author":"W Meng","year":"2023","unstructured":"Meng W, Chen B, Jiang Z, Cai B, Ma L, Guan Y. A comprehensive analysis of MYO6 as a promising biomarker for diagnosis, prognosis, and immunity in clear cell renal cell carcinoma. Transl Cancer Res. 2023;12(8):2071\u201398.","journal-title":"Transl Cancer Res"},{"issue":"6","key":"15329_CR25","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1007\/s11596-022-2625-1","volume":"42","author":"Q Guo","year":"2022","unstructured":"Guo Q, Wang SH, Ji YM, Tong S, Li D, Ding XC, et al. The roles and mechanisms of TRAT1 in the progression of non-small cell lung cancer. Curr Med Sci. 2022;42(6):1186\u2013200.","journal-title":"Curr Med Sci"},{"key":"15329_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.634634","volume":"11","author":"J Ren","year":"2021","unstructured":"Ren J, Yang Y, Li C, Xie L, Hu R, Qin X, et al. A novel prognostic model of early-stage lung adenocarcinoma integrating methylation and immune biomarkers. Front Genet. 2021;11:634634.","journal-title":"Front Genet"},{"key":"15329_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.724741","volume":"12","author":"XS Liu","year":"2021","unstructured":"Liu XS, Zhou LM, Yuan LL, Gao Y, Kui XY, Liu XY, et al. NPM1 is a prognostic biomarker involved in immune infiltration of lung adenocarcinoma and associated with m6A modification and glycolysis. Front Immunol. 2021;12:724741.","journal-title":"Front Immunol"},{"issue":"3","key":"15329_CR28","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.18632\/aging.202292","volume":"13","author":"CY Jin","year":"2020","unstructured":"Jin CY, Du L, Nuerlan AH, Wang XL, Yang YW, Guo R. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma. Aging (Albany NY). 2020;13(3):3518\u201335.","journal-title":"Aging (Albany NY)"},{"issue":"10","key":"15329_CR29","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1158\/2767-9764.CRC-23-0089","volume":"3","author":"A Yadav","year":"2023","unstructured":"Yadav A, Biswas T, Praveen A, Ganguly P, Bhattacharyya A, Verma A, et al. Targeting MALAT1 augments sensitivity to PARP inhibition by impairing homologous recombination in prostate cancer. Cancer Res Commun. 2023;3(10):2044\u201361.","journal-title":"Cancer Res Commun"},{"issue":"3","key":"15329_CR30","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1053\/j.gastro.2014.11.027","volume":"148","author":"SS Tseng-Rogenski","year":"2015","unstructured":"Tseng-Rogenski SS, Hamaya Y, Choi DY, Carethers JM. Interleukin 6 alters localization of hMSH3, leading to DNA mismatch repair defects in colorectal cancer cells. Gastroenterology. 2015;148(3):579\u201389.","journal-title":"Gastroenterology"},{"issue":"8","key":"15329_CR31","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.21037\/jtd-21-583","volume":"13","author":"B Liu","year":"2021","unstructured":"Liu B, Guo S, Li GH, Liu Y, Liu XZ, Yue JB, et al. CHMP4C regulates lung squamous carcinogenesis and progression through cell cycle pathway. J Thorac Dis. 2021;13(8):4762\u201374.","journal-title":"J Thorac Dis"},{"issue":"1","key":"15329_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.path.2019.11.002","volume":"13","author":"R Ruiz-Cordero","year":"2020","unstructured":"Ruiz-Cordero R, Devine WP. Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin. 2020;13(1):17\u201333.","journal-title":"Surg Pathol Clin"},{"issue":"6","key":"15329_CR33","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 2022;40(6):586\u201397.","journal-title":"J Clin Oncol"},{"issue":"12","key":"15329_CR34","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1080\/13543784.2020.1833857","volume":"29","author":"SY Liu","year":"2020","unstructured":"Liu SY, Wu YL. Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020;29(12):1355\u201364.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"15329_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01586-w","volume":"21","author":"LX Zhang","year":"2022","unstructured":"Zhang LX, Gao J, Long X, Zhang PF, Yang X, Zhu SQ, et al. The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p\/CARM1 axis. Mol Cancer. 2022;21(1):110.","journal-title":"Mol Cancer"},{"issue":"3","key":"15329_CR36","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.cellsig.2011.11.005","volume":"24","author":"BH Li","year":"2012","unstructured":"Li BH, Xu SB, Li F, Zou XG, Saimaiti A, Simayi D, et al. Stat6 activity-related Th2 cytokine profile and tumor growth advantage of human colorectal cancer cells in vitro and in vivo. Cell Signal. 2012;24(3):718\u201325.","journal-title":"Cell Signal"},{"issue":"3","key":"15329_CR37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S1074-7613(00)80439-2","volume":"4","author":"MH Kaplan","year":"1996","unstructured":"Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity. 1996;4(3):313\u20139.","journal-title":"Immunity"},{"issue":"20","key":"15329_CR38","first-page":"11067","volume":"15","author":"K Shi","year":"2023","unstructured":"Shi K, Li QY, Zhang YQ, Huang H, Ding DX, Luo WM, et al. HLA-DPA1 overexpression inhibits cancer progression, reduces resistance to cisplatin, and correlates with increased immune infiltration in lung adenocarcinoma. Aging Albany NY. 2023;15(20):11067\u201391.","journal-title":"Aging Albany NY"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15329-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15329-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15329-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:52:51Z","timestamp":1767707571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15329-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15329"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15329-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"1 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided informed consent, and the study was approved by the Ethics Committee (Lun Shen No.113 of 2023) of Henan Provincial People\u2019s Hospital, adhering to the relevant guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}